Cargando…
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385486/ https://www.ncbi.nlm.nih.gov/pubmed/34848822 http://dx.doi.org/10.1038/s41391-021-00477-3 |
| _version_ | 1784769604483022848 |
|---|---|
| author | Penson, David F. Armstrong, Andrew J. Concepcion, Raoul S. Agarwal, Neeraj Olsson, Carl A. Karsh, Lawrence I. Dunshee, Curtis J. Duggan, William Shen, Qi Sugg, Jennifer Haas, Gabriel P. Higano, Celestia S. |
| author_facet | Penson, David F. Armstrong, Andrew J. Concepcion, Raoul S. Agarwal, Neeraj Olsson, Carl A. Karsh, Lawrence I. Dunshee, Curtis J. Duggan, William Shen, Qi Sugg, Jennifer Haas, Gabriel P. Higano, Celestia S. |
| author_sort | Penson, David F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9385486 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93854862022-08-19 Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial Penson, David F. Armstrong, Andrew J. Concepcion, Raoul S. Agarwal, Neeraj Olsson, Carl A. Karsh, Lawrence I. Dunshee, Curtis J. Duggan, William Shen, Qi Sugg, Jennifer Haas, Gabriel P. Higano, Celestia S. Prostate Cancer Prostatic Dis Correction Nature Publishing Group UK 2021-11-30 2022 /pmc/articles/PMC9385486/ /pubmed/34848822 http://dx.doi.org/10.1038/s41391-021-00477-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Penson, David F. Armstrong, Andrew J. Concepcion, Raoul S. Agarwal, Neeraj Olsson, Carl A. Karsh, Lawrence I. Dunshee, Curtis J. Duggan, William Shen, Qi Sugg, Jennifer Haas, Gabriel P. Higano, Celestia S. Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial |
| title | Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial |
| title_full | Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial |
| title_fullStr | Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial |
| title_full_unstemmed | Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial |
| title_short | Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial |
| title_sort | correction: enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the strive trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385486/ https://www.ncbi.nlm.nih.gov/pubmed/34848822 http://dx.doi.org/10.1038/s41391-021-00477-3 |
| work_keys_str_mv | AT pensondavidf correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT armstrongandrewj correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT concepcionraouls correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT agarwalneeraj correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT olssoncarla correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT karshlawrencei correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT dunsheecurtisj correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT dugganwilliam correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT shenqi correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT suggjennifer correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT haasgabrielp correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial AT higanocelestias correctionenzalutamideversusbicalutamideinpatientswithnonmetastaticcastrationresistantprostatecanceraprespecifiedsubgroupanalysisofthestrivetrial |